YU42903A - Kondenzovani derivati purina kao antagonisti a1 receptora adenozina - Google Patents
Kondenzovani derivati purina kao antagonisti a1 receptora adenozinaInfo
- Publication number
- YU42903A YU42903A YU42903A YUP42903A YU42903A YU 42903 A YU42903 A YU 42903A YU 42903 A YU42903 A YU 42903A YU P42903 A YUP42903 A YU P42903A YU 42903 A YU42903 A YU 42903A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- receptor antagonists
- adenosine receptor
- purine derivatives
- condensed purine
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Otkrivena su jedinjenja formule I i II kao antagonisti podtipa A1 receptora adenozina. Ova jedinjenja su korisna za tretman različitih bolesti i poremećaja, uključujući sistemsku hipertenziju, oštećenje bubrega, dijabetes, astmu i edematozna stanja, kongestivnu srčanu manu i bubrežnu disfunkciju.[Compounds of Formula I and II are disclosed as antagonists of subtype A1 adenosine receptors. These compounds are useful for treatment of various diseases and disorders, including systemic hypertension, renal failure, diabetes, asthma, an edematous condition, congestive heart failure, and renal dysfunction.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25065800P | 2000-12-01 | 2000-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU42903A true YU42903A (sh) | 2006-05-25 |
Family
ID=22948640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU42903A YU42903A (sh) | 2000-12-01 | 2001-11-30 | Kondenzovani derivati purina kao antagonisti a1 receptora adenozina |
Country Status (33)
Country | Link |
---|---|
US (2) | US6605601B2 (sh) |
EP (1) | EP1347981B1 (sh) |
JP (2) | JP2004514723A (sh) |
KR (1) | KR20040011439A (sh) |
CN (1) | CN100497340C (sh) |
AR (1) | AR035400A1 (sh) |
AT (1) | ATE394402T1 (sh) |
AU (2) | AU1997702A (sh) |
BG (1) | BG107849A (sh) |
BR (1) | BR0115833A (sh) |
CA (1) | CA2430508C (sh) |
CZ (1) | CZ20031513A3 (sh) |
DE (1) | DE60133931D1 (sh) |
EA (1) | EA009814B1 (sh) |
EE (1) | EE200300260A (sh) |
ES (1) | ES2305139T3 (sh) |
GE (1) | GEP20094697B (sh) |
HK (1) | HK1059927A1 (sh) |
HU (1) | HUP0400530A3 (sh) |
IL (1) | IL156046A0 (sh) |
IS (1) | IS6821A (sh) |
MX (1) | MXPA03004857A (sh) |
MY (1) | MY127120A (sh) |
NO (1) | NO20032483L (sh) |
NZ (1) | NZ526511A (sh) |
PL (1) | PL362642A1 (sh) |
SK (1) | SK6552003A3 (sh) |
TR (1) | TR200300766T2 (sh) |
TW (1) | TWI293301B (sh) |
UA (1) | UA75625C2 (sh) |
WO (1) | WO2002044182A1 (sh) |
YU (1) | YU42903A (sh) |
ZA (2) | ZA200304067B (sh) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7005430B2 (en) * | 1999-12-24 | 2006-02-28 | Kyowa Hakko Kogyo Co., Ltd. | Fused purine derivatives |
CZ20031513A3 (cs) * | 2000-12-01 | 2003-09-17 | Biogen, Inc. | Kondenzované purinové deriváty jako antagonisty A1 adenosinového receptoru |
US7202252B2 (en) * | 2003-02-19 | 2007-04-10 | Endacea, Inc. | A1 adenosine receptor antagonists |
US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
CA2522971A1 (en) * | 2003-04-25 | 2004-11-11 | Novacardia, Inc. | Method of improved diuresis in individuals with impaired renal function |
CA2523763A1 (en) * | 2003-04-25 | 2004-11-11 | Kyowa Hakko Kogyo Co., Ltd. | Fused pyrimidine derivative |
CA2528385C (en) * | 2003-06-06 | 2011-03-15 | Endacea, Inc. | A1 adenosine receptor antogonists |
EP1863815A1 (en) * | 2005-03-11 | 2007-12-12 | Aderis Pharmaceuticals, Inc. | Substituted 9-alkyladenines and the use thereof |
US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
WO2007117549A2 (en) * | 2006-04-06 | 2007-10-18 | Novacardia, Inc. | Co-administration of adenosine a1 receptor antagonists and anticonvulsants |
EP2431368B1 (en) | 2006-05-19 | 2014-08-27 | AbbVie Bahamas Ltd. | CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives |
CN101466383A (zh) * | 2006-06-16 | 2009-06-24 | 美国诺华卡迪亚公司 | 包含低频率投与aa1ra的肾功能延长改善 |
WO2007150026A2 (en) | 2006-06-23 | 2007-12-27 | Incyte Corporation | Purinone derivatives as hm74a agonists |
AU2007260851B2 (en) | 2006-06-23 | 2013-01-17 | Incyte Corporation | Purinone derivatives as HM74a agonists |
US20090197900A1 (en) * | 2007-03-29 | 2009-08-06 | Howard Dittrich | Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist |
WO2008121882A1 (en) * | 2007-03-29 | 2008-10-09 | Novacardia, Inc. | Improved methods of administration of adenosine a1 receptor antagonists |
WO2011063268A2 (en) * | 2009-11-19 | 2011-05-26 | Biogen Idec Ma Inc | Novel synthetic methods |
US20130109645A1 (en) | 2010-03-31 | 2013-05-02 | The united States of America,as represented by Secretary,Dept.,of Health and Human Services | Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders |
KR20200106176A (ko) | 2018-01-04 | 2020-09-11 | 임페티스 바이오사이언시즈 엘티디. | 삼환식 화합물, 삼환식 화합물을 포함하는 조성물 및 이의 의약적 용도 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06102662B2 (ja) * | 1989-09-01 | 1994-12-14 | 協和醗酵工業株式会社 | キサンチン誘導体 |
CA2028235C (en) * | 1989-10-20 | 1997-01-21 | Fumio Suzuki | Condensed purine derivatives |
ATE258171T1 (de) | 1991-09-23 | 2004-02-15 | Univ Florida State | Metallalkoxide |
CA2239881A1 (en) * | 1996-10-07 | 1998-04-16 | Nobuo Kosaka | Condensed purine derivatives |
AU740770B2 (en) * | 1997-06-18 | 2001-11-15 | Aderis Pharmaceuticals, Inc. | Compositions and methods for preventing restenosis following revascularization procedures |
ES2284256T3 (es) | 1998-07-02 | 2007-11-01 | Kyowa Hakko Kogyo Co., Ltd. | Medicamentos para la diabetes. |
US7005430B2 (en) * | 1999-12-24 | 2006-02-28 | Kyowa Hakko Kogyo Co., Ltd. | Fused purine derivatives |
CZ20031513A3 (cs) * | 2000-12-01 | 2003-09-17 | Biogen, Inc. | Kondenzované purinové deriváty jako antagonisty A1 adenosinového receptoru |
-
2001
- 2001-11-30 CZ CZ20031513A patent/CZ20031513A3/cs unknown
- 2001-11-30 AU AU1997702A patent/AU1997702A/xx active Pending
- 2001-11-30 AT AT01998550T patent/ATE394402T1/de not_active IP Right Cessation
- 2001-11-30 IL IL15604601A patent/IL156046A0/xx unknown
- 2001-11-30 UA UA2003066041A patent/UA75625C2/uk unknown
- 2001-11-30 KR KR10-2003-7007322A patent/KR20040011439A/ko active IP Right Grant
- 2001-11-30 YU YU42903A patent/YU42903A/sh unknown
- 2001-11-30 AR ARP010105594A patent/AR035400A1/es unknown
- 2001-11-30 EE EEP200300260A patent/EE200300260A/xx unknown
- 2001-11-30 CN CNB018208711A patent/CN100497340C/zh not_active Expired - Fee Related
- 2001-11-30 EA EA200300629A patent/EA009814B1/ru not_active IP Right Cessation
- 2001-11-30 DE DE60133931T patent/DE60133931D1/de not_active Expired - Lifetime
- 2001-11-30 ES ES01998550T patent/ES2305139T3/es not_active Expired - Lifetime
- 2001-11-30 BR BR0115833-3A patent/BR0115833A/pt not_active Application Discontinuation
- 2001-11-30 TW TW090129678A patent/TWI293301B/zh active
- 2001-11-30 NZ NZ526511A patent/NZ526511A/en unknown
- 2001-11-30 AU AU2002219977A patent/AU2002219977B2/en not_active Ceased
- 2001-11-30 PL PL01362642A patent/PL362642A1/xx not_active Application Discontinuation
- 2001-11-30 GE GEAP20017016A patent/GEP20094697B/en unknown
- 2001-11-30 TR TR2003/00766T patent/TR200300766T2/xx unknown
- 2001-11-30 US US09/997,740 patent/US6605601B2/en not_active Expired - Fee Related
- 2001-11-30 JP JP2002546552A patent/JP2004514723A/ja active Pending
- 2001-11-30 HU HU0400530A patent/HUP0400530A3/hu unknown
- 2001-11-30 EP EP01998550A patent/EP1347981B1/en not_active Expired - Lifetime
- 2001-11-30 CA CA2430508A patent/CA2430508C/en not_active Expired - Fee Related
- 2001-11-30 SK SK655-2003A patent/SK6552003A3/sk not_active Application Discontinuation
- 2001-11-30 MX MXPA03004857A patent/MXPA03004857A/es active IP Right Grant
- 2001-11-30 WO PCT/US2001/044991 patent/WO2002044182A1/en active IP Right Grant
- 2001-11-30 MY MYPI20015481A patent/MY127120A/en unknown
-
2003
- 2003-05-20 IS IS6821A patent/IS6821A/is unknown
- 2003-05-26 ZA ZA200304067A patent/ZA200304067B/en unknown
- 2003-05-27 US US10/446,573 patent/US7022686B2/en not_active Expired - Fee Related
- 2003-05-27 BG BG107849A patent/BG107849A/bg unknown
- 2003-06-02 NO NO20032483A patent/NO20032483L/no not_active Application Discontinuation
-
2004
- 2004-02-27 HK HK04101469.6A patent/HK1059927A1/xx not_active IP Right Cessation
- 2004-10-28 ZA ZA200408755A patent/ZA200408755B/xx unknown
-
2009
- 2009-12-07 JP JP2009278047A patent/JP2010053148A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU42903A (sh) | Kondenzovani derivati purina kao antagonisti a1 receptora adenozina | |
YU33802A (sh) | Policikloalkilpurini kao antagonisti adenozinskih receptora | |
MXPA02001764A (es) | Compuestos heteropoliciclicos y su uso como antagonistas de receptor de glutamato metabotropico. | |
MY141559A (en) | Triazole derivatives as tachykinin receptor antagonists | |
DK1444233T3 (da) | A2B-adenosinreceptorantagonister | |
AU640417B2 (en) | Substituted 5-((tetrazolyl)alkenyl)imidazoles | |
EP1074549A3 (en) | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors | |
TR200002097A2 (tr) | Triazol ve imidazol türevleri | |
JP2004511522A5 (sh) | ||
EP1398029A8 (en) | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives | |
ATE119524T1 (de) | Substituierte n-(imidazolyl)alkyl-alanin- derivate. | |
EP1775297A3 (en) | Adenosine receptor antagonists and methods of making and using the same | |
ATE429421T1 (de) | Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten | |
PL340711A1 (en) | Derivatives of 5-(2-imidazolinamino)-benzimidazole, their production and application of them as antagonists of alpha-adrenergic receptors of improved metabolic stability | |
WO2002014294A3 (en) | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function | |
WO2002014275A3 (en) | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function | |
WO2002017899A3 (en) | Regulation of angiogenesis via modulation of edg receptor mediated signal transduction comprising sphingosine-1-phosphate administration | |
WO2004099148A8 (en) | Substituted pyrimidine derivatives | |
ATE227276T1 (de) | Neue pyrimidinderivate | |
MY118704A (en) | Process for preparation of eprosartan | |
AU2251801A (en) | Piperidine derivatives and their use as serotonin receptor antagonists | |
WO2000076457A3 (en) | Il-8 receptor antagonists | |
EP1172106A3 (en) | Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists | |
TH62169A (th) | A1อะดีโนซีน รีเซพเตอร์ แอนทาโกนิสท์ | |
EP1582519A3 (en) | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |